CORRESPONDENCE
PBD treatment of cancer of the head of the pancreas Niels A. van der Gaag and Dirk J. Gouma we thank neoptolemos and Halloran for their critical commentary (PBD-better stents in specialized centers are needed. Nat. Rev. Clin. Oncol. 7, 244-246) 1 of the ongoing debate and our recent trial concerning pre operative biliary drainage (PBD). 2 However, we would like to clarify some misunder standings by the authors, as well as quest ionable interpretations from other studies. Moreover, the commentary did not clearly present the general clinical dilemma for the physician; that is, whether to perform PBD in a patient with jaundice, suspected to have a pancreatic malignancy and elig ible for surgery, but without information of underlying pathology at this stage. Our scenario analysis of surgery following PBD versus surgery alone found no benefit of routine PBD. 2 neoptolemos and Halloran commented that our study was not blinded, 1 but the nature of our trial-evaluating the conse quences of an additional invasive proce dure-does not allow for blinding. initial stenting for PBD was performed mostly in district (community) hospitals and success rates did not differ significantly with those of university centers. if failure occurred, the patient was referred to a tertiary center for a second attempt or, ultimately, percu taneous transhepatic drainage (PtD). this stepup approach led to a 96% success rate for stent placement. Of note, the errone ously quoted 25% rescue PtD rate was in fact 12%. regarding antibiotic prophylaxis, current literature does not dictate routine anti biotics for PBD through endoscopy. 3, 4 Placement of plastic stents for PBD is common practice worldwide, owing to easy availability and low costs, and is common practice in the uK, 5 including at the commentary authors' institution. Costly selfexpanding metal stents are curr ently recommended for palliation, but a high level of evidence does not yet exist for their use for PBD.
6-9 these stents might lead to a lower complication rate compared with plastic stents, but complication rates associated with stenting will always be higher than in strategies without.
with respect to diagnostics we believe that further investigations are not indi cated for patients with jaundice, who on Ct scan display a lesion in the pancreatic head without metastasis and extensive vascular ingrowth. these findings will not change the treatment strategy, and these patients should always proceed to surgical explora tion. in patients without a lesion, additional endoscopic ultrasound might be performed. at this stage routine diagnostic laparoscopy has limited additional value. 10 neoptolemos and Halloran claim that mortality rates of 13% and 15% are exces sive. 1 However, instead of the regularly reported 30day inhospital mortality fol lowing resection, we employed a 120day obser vation period following randomiza tion. in this period we observed all patients, including those that were judged unresect able intraoperatively or that were not oper ated upon, and who died shortly after from progressive disease. thus, the mortality we reported is entirely incomparable to the studies referred to in the commentary. 11, 12 although our study was carried out in the setting of general practice with medium volume and highvolume experience (the entry condition of performing at least 10 resections per year was made in an earlier study) 13 we agree with the authors that treat ment of patients with pancreatic cancer should be centralized in high volume centers.
the claim that periampullary tumors have better interventional outcomes has no evidential grounds. On the contrary, extensive tumor growth around the papilla can be a complicating factor for the endo scopist. the nondilated pancreatic duct in periam pullary tumors, compared with pan creatic adenocarcinomas, is an established risk factor for anastomotic leakage. 14, 15 Furthermore, we performed a logistic regression analysis for the primary end point with correction for several predefined risk factors inclu ding tumor pathology and BMi (differences between the groups were merely the consequence of randomization).
suggestions about performing PBD in light of administration of neoadjuvant (chemoradiation) therapy, management of cholangitis or severe obstructive jaundice are in agreement with the discussion in our paper, but so far there is no evidence for these statements. we subscribe to the suggestion of neoptolemos and Halloran that techniques that allow for a higher stent patency for PBD should be employed for these subgroups of patients, and that the statement of selfexpanding metal stents as a better drainage option should be invest igated. Our randomized trial has demon strated that a PBD strategy increases complications significantly. the best option is not to postpone surgery.
